Home/Pipeline/Amdizalisib (HMPL-689)

Amdizalisib (HMPL-689)

Hematological Malignancies

Phase 3Registrational

Key Facts

Indication

Hematological Malignancies

Phase

Phase 3

Status

Registrational

Company

HUTCHMED

About HUTCHMED

HUTCHMED is a leading, innovation-driven biopharma focused on oncology and immunology, with a strategy of 'in China, for the world.' The company has successfully brought novel drugs like fruquintinib (ELUNATE®) to market in China and achieved its first global approval with Takeda. Its business model integrates discovery, development, manufacturing, and commercialization, supported by a deep pipeline of both internally discovered and in-licensed assets. HUTCHMED aims to become a global biopharmaceutical leader by advancing its pipeline through strategic global partnerships.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Hematological Malignancies Drugs

Drug	Company	Phase	Status
HMPL-A83	HUTCHMED	Phase 1	Active
DFTX-301	Definium Therapeutics	Preclinical	Discovery
Preclinical Pipeline	Autolus Therapeutics	Pre-clinical	Active
Gamma Delta T Cell Platform	Adicet Bio	Preclinical	Research